Inari Medical (NARI) Stock Forecast, Price Target & Predictions
NARI Stock Forecast
Inari Medical stock forecast is as follows: an average price target of $70.33 (represents a 59.48% upside from NARI’s last price of $44.10) and a rating consensus of 'Buy', based on 10 wall street analysts offering a 1-year stock forecast.
NARI Price Target
The average price target for Inari Medical (NARI) is $70.33 based on 1-year price targets from 10 Wall Street analysts in the past 3 months, with a price target range of $100.00 to $50.00. This represents a potential 59.48% upside from NARI's last price of $44.10.
NARI Analyst Ratings
According to 10 Wall Street analysts, Inari Medical's rating consensus is 'Buy'. The analyst rating breakdown for NARI stock is 0 'Strong Buy' (0.00%), 7 'Buy' (70.00%), 2 'Hold' (20.00%), 0 'Sell' (0.00%), and 1 'Strong Sell' (10.00%).
Inari Medical Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 17, 2024 | Mathew Blackman | Stifel Nicolaus | $50.00 | $44.10 | 13.38% | 13.38% |
| Aug 09, 2024 | Pito Chickering | Deutsche Bank | $68.00 | $48.72 | 39.57% | 54.20% |
| Jul 31, 2024 | David Rescott | Robert W. Baird | $63.00 | $52.11 | 20.90% | 42.86% |
| Jul 31, 2024 | Larry Biegelsen | Wells Fargo | $65.00 | $52.11 | 24.74% | 47.39% |
| Jul 16, 2024 | Richard Newitter | Truist Financial | $60.00 | $54.97 | 9.15% | 36.05% |
| May 01, 2024 | Adam Maeder | Piper Sandler | $50.00 | $44.30 | 12.87% | 13.38% |
| Jan 06, 2023 | - | Morgan Stanley | $83.00 | $66.69 | 24.45% | 88.21% |
| Dec 20, 2022 | - | Truist Financial | $75.00 | $67.13 | 11.73% | 70.07% |
| Sep 16, 2022 | - | Canaccord Genuity | $94.00 | $68.64 | 36.94% | 113.15% |
| Jul 15, 2022 | - | Morgan Stanley | $93.00 | $73.52 | 26.50% | 110.88% |
The latest Inari Medical stock forecast, released on Sep 17, 2024 by Mathew Blackman from Stifel Nicolaus, set a price target of $50.00, which represents a 13.38% increase from the stock price at the time of the forecast ($44.10), and a 13.38% increase from NARI last price ($44.10).
Inari Medical Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 5 | 6 |
| Avg Price Target | $50.00 | $61.20 | $59.33 |
| Last Closing Price | $44.10 | $44.10 | $44.10 |
| Upside/Downside | 13.38% | 38.78% | 34.54% |
In the current month, the average price target of Inari Medical stock is $50.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 13.38% increase as opposed to Inari Medical's last price of $44.10. This month's average price target is down -18.30% compared to last quarter, and down -15.73% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 26, 2024 | Truist Financial | Underperform | Underperform | Hold |
| Aug 26, 2024 | Wells Fargo | Buy | Buy | Hold |
| Aug 26, 2024 | Piper Sandler | Neutral | Neutral | Hold |
| Aug 09, 2024 | Deutsche Bank | - | Buy | Initialise |
| Jul 31, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| Jul 18, 2024 | Needham | - | Hold | Downgrade |
| Jul 15, 2024 | Morgan Stanley | Outperform | Outperform | Hold |
| May 01, 2024 | Piper Sandler | Neutral | Neutral | Hold |
| Apr 12, 2024 | Truist Financial | Underperform | Underperform | Hold |
| Apr 12, 2024 | William Blair | Buy | Buy | Hold |
Inari Medical's last stock rating was published by Truist Financial on Aug 26, 2024. The company gave NARI a "Underperform" rating, the same as its previous rate.
Inari Medical Financial Forecast
Inari Medical Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $132.09M | $126.37M | $119.00M | $116.17M | $107.77M | $96.20M | - | $86.75M | $83.22M | $72.92M | $63.45M | $57.40M | $48.61M | $38.72M | $25.39M |
| Avg Forecast | $224.14M | $211.36M | $205.06M | $199.08M | $189.93M | $178.58M | $171.85M | $167.98M | $160.61M | $150.48M | $143.79M | $137.83M | $131.79M | $121.92M | $116.67M | $110.56M | $104.85M | $90.83M | $87.80M | $83.60M | $78.15M | $63.04M | $59.65M | $55.14M | $42.87M | $26.53M | $12.97M |
| High Forecast | $226.57M | $213.65M | $207.28M | $201.24M | $191.98M | $180.51M | $173.71M | $169.80M | $162.35M | $152.06M | $145.35M | $139.32M | $132.03M | $123.25M | $117.93M | $111.76M | $105.99M | $91.81M | $87.80M | $85.93M | $80.32M | $64.79M | $61.30M | $56.67M | $44.06M | $27.27M | $13.33M |
| Low Forecast | $222.78M | $210.08M | $203.82M | $197.88M | $188.78M | $177.50M | $170.81M | $166.96M | $159.64M | $149.93M | $142.92M | $137.00M | $131.53M | $121.19M | $115.96M | $109.89M | $104.22M | $90.28M | $87.80M | $82.43M | $77.05M | $62.15M | $58.81M | $54.36M | $42.26M | $26.16M | $12.79M |
| # Analysts | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 3 | 4 | 8 | 5 | 4 | 4 | 7 | 4 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.00% | 1.04% | 1.02% | 1.05% | 1.03% | 1.06% | - | 1.04% | 1.06% | 1.16% | 1.06% | 1.04% | 1.13% | 1.46% | 1.96% |
Inari Medical's average Quarter revenue forecast for Mar 24 based on 4 analysts is $137.83M, with a low forecast of $137.00M, and a high forecast of $139.32M. NARI's average Quarter revenue forecast represents a 4.34% increase compared to the company's last Quarter revenue of $132.09M (Dec 23).
Inari Medical EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 3 | 4 | 8 | 5 | 4 | 4 | 7 | 4 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-10.78M | $2.11M | $5.21M | $1.82M | $-2.84M | $-7.50M | - | $-1.39M | $3.42M | $-1.67M | $5.01M | $8.53M | $7.51M | $7.11M | $-3.04M |
| Avg Forecast | $7.22M | $6.81M | $6.61M | $6.41M | $6.12M | $5.75M | $5.54M | $5.41M | $5.18M | $4.85M | $4.63M | $-1.90M | $4.25M | $3.93M | $3.76M | $-1.73M | $3.38M | $-2.77M | $2.83M | $-1.85M | $4.56M | $-2.19M | $6.13M | $5.63M | $1.38M | $854.94K | $-3.38M |
| High Forecast | $7.30M | $6.88M | $6.68M | $6.48M | $6.19M | $5.82M | $5.60M | $5.47M | $5.23M | $4.90M | $4.68M | $-1.52M | $4.25M | $3.97M | $3.80M | $-1.39M | $3.41M | $-2.21M | $2.83M | $-1.48M | $5.47M | $-1.75M | $7.35M | $6.75M | $1.42M | $878.72K | $-2.70M |
| Low Forecast | $7.18M | $6.77M | $6.57M | $6.38M | $6.08M | $5.72M | $5.50M | $5.38M | $5.14M | $4.83M | $4.61M | $-2.29M | $4.24M | $3.90M | $3.74M | $-2.08M | $3.36M | $-3.32M | $2.83M | $-2.22M | $3.65M | $-2.62M | $4.90M | $4.50M | $1.36M | $842.95K | $-4.06M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -2.54% | 0.54% | 1.39% | -1.05% | -0.84% | 2.71% | - | 0.75% | 0.75% | 0.76% | 0.82% | 1.52% | 5.44% | 8.31% | 0.90% |
7 analysts predict NARI's average Quarter EBITDA for Dec 23 to be $4.25M, with a high of $4.25M and a low of $4.24M. This is 100.96% upper than Inari Medical's previous annual EBITDA (Sep 23) of $2.11M.
Inari Medical Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 3 | 4 | 8 | 5 | 4 | 4 | 7 | 4 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-4.67M | $3.16M | $2.08M | $-2.22M | $-5.80M | $-10.15M | - | $-3.18M | $1.11M | $-2.80M | $4.07M | $7.47M | $6.99M | $6.50M | $-3.80M |
| Avg Forecast | $9.98M | $7.68M | $6.68M | $2.81M | $5.85M | $3.48M | $2.02M | $-849.29K | $-3.44M | $-6.28M | $-11.23M | $-4.29M | $356.99K | $799.46K | $-7.30M | $-3.90M | $-9.92M | $-4.64M | $-13.33M | $-4.17M | $1.48M | $-3.67M | $4.97M | $4.93M | $720.96K | $29.23M | $-4.23M |
| High Forecast | $10.12M | $7.79M | $6.78M | $2.85M | $5.93M | $3.53M | $2.05M | $-842.61K | $-3.41M | $-1.14M | $-11.14M | $-3.43M | $2.86M | $810.71K | $-7.24M | $-3.12M | $-9.84M | $-3.71M | $-13.33M | $-3.34M | $1.77M | $-2.94M | $5.97M | $5.92M | $747.03K | $35.08M | $-3.38M |
| Low Forecast | $9.90M | $7.62M | $6.63M | $2.79M | $5.81M | $3.45M | $2.01M | $-861.24K | $-3.49M | $-10.27M | $-11.38M | $-5.15M | $-1.43M | $793.17K | $-7.40M | $-4.68M | $-10.06M | $-5.57M | $-13.33M | $-5.01M | $1.18M | $-4.40M | $3.98M | $3.94M | $707.81K | $23.39M | $-5.07M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -13.07% | 3.96% | -0.29% | 0.57% | 0.58% | 2.19% | - | 0.76% | 0.75% | 0.76% | 0.82% | 1.52% | 9.69% | 0.22% | 0.90% |
Inari Medical's average Quarter net income forecast for Dec 23 is $356.99K, with a range of $-1.43M to $2.86M. NARI's average Quarter net income forecast represents a -88.71% decrease compared to the company's last Quarter net income of $3.16M (Sep 23).
Inari Medical SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 3 | 4 | 8 | 5 | 4 | 4 | 7 | 4 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $101.49M | $88.28M | $85.59M | $85.70M | $80.12M | $75.83M | - | $63.73M | $54.47M | $56.10M | $42.90M | $36.90M | $31.39M | $23.08M | $18.88M |
| Avg Forecast | $157.78M | $148.78M | $144.35M | $140.14M | $133.69M | $125.70M | $120.97M | $118.25M | $113.06M | $105.93M | $101.22M | $87.40M | $92.77M | $85.83M | $82.13M | $79.45M | $73.81M | $63.94M | $61.81M | $58.85M | $72.62M | $44.37M | $52.43M | $24.35M | $30.17M | $18.68M | $9.13M |
| High Forecast | $159.49M | $150.39M | $145.91M | $141.66M | $135.14M | $127.07M | $122.28M | $119.53M | $114.28M | $107.04M | $102.31M | $104.88M | $92.94M | $86.76M | $83.02M | $95.34M | $74.61M | $64.63M | $61.81M | $60.49M | $87.15M | $45.61M | $62.92M | $29.22M | $31.01M | $19.20M | $9.38M |
| Low Forecast | $156.82M | $147.88M | $143.47M | $139.29M | $132.89M | $124.94M | $120.24M | $117.53M | $112.38M | $105.54M | $100.61M | $69.92M | $92.59M | $85.31M | $81.63M | $63.56M | $73.36M | $63.55M | $61.81M | $58.03M | $58.10M | $43.75M | $41.94M | $19.48M | $29.75M | $18.42M | $9.00M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.09% | 1.03% | 1.04% | 1.08% | 1.09% | 1.19% | - | 1.08% | 0.75% | 1.26% | 0.82% | 1.52% | 1.04% | 1.24% | 2.07% |
Inari Medical's average Quarter SG&A projection for Mar 24 is $87.40M, based on 4 Wall Street analysts, with a range of $69.92M to $104.88M. The forecast indicates a -13.89% fall compared to NARI last annual SG&A of $101.49M (Dec 23).
Inari Medical EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 3 | 4 | 8 | 5 | 4 | 4 | 7 | 4 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.08 | $0.06 | $0.04 | $-0.04 | $-0.11 | $-0.19 | - | $-0.06 | $0.02 | $-0.06 | $0.08 | $0.15 | $0.14 | $0.13 | $-0.16 |
| Avg Forecast | $0.17 | $0.13 | $0.11 | $0.05 | $0.10 | $0.06 | $0.03 | $-0.01 | $-0.06 | $-0.11 | $-0.19 | $-0.16 | $0.01 | $0.01 | $-0.13 | $-0.23 | $-0.17 | $-0.25 | $-0.23 | $-0.08 | $0.04 | $-0.07 | $0.08 | $0.06 | $0.01 | $-0.04 | $-0.17 |
| High Forecast | $0.17 | $0.13 | $0.12 | $0.05 | $0.10 | $0.06 | $0.04 | $-0.01 | $-0.06 | $-0.02 | $-0.19 | $-0.16 | $0.05 | $0.01 | $-0.12 | $-0.22 | $-0.17 | $-0.25 | $-0.23 | $-0.08 | $0.04 | $-0.07 | $0.08 | $0.06 | $0.01 | $-0.04 | $-0.17 |
| Low Forecast | $0.17 | $0.13 | $0.11 | $0.05 | $0.10 | $0.06 | $0.03 | $-0.01 | $-0.06 | $-0.18 | $-0.20 | $-0.16 | $-0.02 | $0.01 | $-0.13 | $-0.23 | $-0.17 | $-0.25 | $-0.23 | $-0.08 | $0.04 | $-0.07 | $0.08 | $0.06 | $0.01 | $-0.04 | $-0.18 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -13.39% | 4.01% | -0.32% | 0.18% | 0.64% | 0.77% | - | 0.80% | 0.59% | 0.88% | 0.98% | 2.65% | 11.19% | -3.42% | 0.91% |
According to 7 Wall Street analysts, Inari Medical's projected average Quarter EPS for Dec 23 is $0.01, with a low estimate of $-0.02 and a high estimate of $0.05. This represents a -88.86% decrease compared to NARI previous annual EPS of $0.06 (Sep 23).
Inari Medical Peer Comparison by Price Target
NARI Forecast FAQ
Is Inari Medical a good buy?
Yes, according to 10 Wall Street analysts, Inari Medical (NARI) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 70.00% of NARI's total ratings.
What is NARI's price target?
Inari Medical (NARI) average price target is $70.33 with a range of $50 to $100, implying a 59.48% from its last price of $44.1. The data is based on 10 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Inari Medical stock go up soon?
According to Wall Street analysts' prediction for NARI stock, the company can go up by 59.48% (from the last price of $44.1 to the average price target of $70.33), up by 126.76% based on the highest stock price target, and up by 13.38% based on the lowest stock price target.
Can Inari Medical stock reach $70?
NARI's average twelve months analyst stock price target of $70.33 supports the claim that Inari Medical can reach $70 in the near future.
What is Inari Medical's current price target trend?
1 Wall Street analyst forecast a $50 price target for Inari Medical (NARI) this month, up 13.38% from its last price of $44.1. Compared to the last 3 and 12 months, the average price target increased by 38.78% and increased by 34.54%, respectively.
What are Inari Medical's analysts' financial forecasts?
Inari Medical's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $708.33M (high $716.01M, low $704.05M), average EBITDA is $22.82M (high $23.07M, low $22.69M), average net income is $10.5M (high $10.67M, low $10.4M), average SG&A $498.62M (high $504.02M, low $495.6M), and average EPS is $0.181 (high $0.183, low $0.179). NARI's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $839.64M (high $848.73M, low $834.56M), average EBITDA is $27.05M (high $27.35M, low $26.89M), average net income is $27.15M (high $27.53M, low $26.94M), average SG&A $591.05M (high $597.45M, low $587.47M), and average EPS is $0.467 (high $0.474, low $0.463).
Did the NARI's actual financial results beat the analysts' financial forecasts?
Based on Inari Medical's last annual report (Dec 2023), the company's revenue was $493.63M, beating the average analysts forecast of $480.94M by 2.64%. Apple's EBITDA was $-14.032M, missing the average prediction of $10.2M by -237.54%. The company's net income was $-1.636M, missing the average estimation of $-10.044M by -83.71%. Apple's SG&A was $361.06M, beating the average forecast of $340.17M by 6.14%. Lastly, the company's EPS was $-0.0288, missing the average prediction of $-0.332 by -91.32%. In terms of the last quarterly report (Dec 2023), Inari Medical's revenue was $132.09M, beating the average analysts' forecast of $131.79M by 0.23%. The company's EBITDA was $-10.782M, missing the average prediction of $4.25M by -353.92%. Inari Medical's net income was $-4.665M, missing the average estimation of $356.99K by -1406.74%. The company's SG&A was $101.49M, beating the average forecast of $92.77M by 9.40%. Lastly, the company's EPS was $-0.0822, missing the average prediction of $0.00614 by -1438.76%